Tiffany Powell, MD
Family Medicine · Moneta, VANPI 1255318978
Payments from drug & device makers
Across 438 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$817
- Mannkind Corporation$694
- AbbVie$619
- Johnson & Johnson$418
- Amgen$374
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,52999%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 77 | $1,263 |
| Novo Nordisk | 43 | $817 |
| Mannkind Corporation | 75 | $694 |
| AbbVie(2 entities) | 53 | $619 |
| Johnson & Johnson | 28 | $418 |
| Amgen | 28 | $374 |
| Idorsia Pharmaceuticals US Inc | 7 | $215 |
| GSK | 13 | $205 |
| Lilly USA, LLC | 10 | $176 |
| Astellas Pharma US Inc | 8 | $170 |
| Abbott | 9 | $161 |
| Sanofi-aventis U.S. LLC | 9 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $152 |
| Kowa Pharmaceuticals America, Inc. | 8 | $113 |
| Novartis | 6 | $109 |
| Pfizer | 6 | $107 |
| Biohaven Pharmaceuticals, Inc. | 5 | $91 |
| Amarin Pharma, Inc. | 6 | $89 |
| Merck | 5 | $88 |
| Boehringer Ingelheim | 5 | $85 |
| Sanofi Pasteur Inc. | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $76 |
| ANI Pharmaceuticals, Inc. | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 1 | $43 |
| Exact Sciences | 2 | $39 |
| Eisai Inc. | 2 | $29 |
| Almatica Pharma LLC | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Si-bone, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUVIVIQ$125
How this compares
$6,610 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 24 | $38,475 |
| JardianceEmpagliflozin | 20 | $29,032 |
| OzempicSemaglutide | 15 | $28,099 |
| EliquisApixaban | 41 | $23,674 |
| FarxigaDapagliflozin Propanediol | 29 | $22,220 |
| XareltoRivaroxaban | 15 | $18,980 |
| LinzessLinaclotide | 13 | $17,451 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,829 |
| MyrbetriqMirabegron | 11 | $15,367 |
| MounjaroTirzepatide | 13 | $13,369 |
| BelsomraSuvorexant | 13 | $8,044 |
| Repatha SureclickEvolocumab | 11 | $6,201 |
| LivaloPitavastatin Calcium | 12 | $3,703 |
| Pitavastatin Calcium | 13 | $3,681 |
| Nebivolol Hcl | 37 | $2,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $817 | $66,57439 claims |
| Boehringer IngelheimJardiance | $85 | $29,03220 claims |
| PfizerEliquis | $107 | $23,67441 claims |
| AstraZenecaFarxiga | $1,263 | $22,22029 claims |
| AbbVieLinzess, Synthroid | $619 | $19,15647 claims |
| Johnson & JohnsonXarelto | $418 | $18,98015 claims |
| GSKTrelegy Ellipta | $205 | $16,82922 claims |
| Astellas Pharma US IncMyrbetriq | $170 | $15,36711 claims |
| Lilly USA, LLCMounjaro | $176 | $13,36913 claims |
| MerckBelsomra | $88 | $8,04413 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $113 | $3,70312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Moneta
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.